Oculus Innovative Sciences Inc.
Oculus Innovative Sciences, Inc. is a specialty device and pharmaceutical company. The Company develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in both humans and animals. The Company offers wound care products which are sold into the human and animal healthcare markets in the United States, Mexico and Europe. The Company also operates a microbiology contract testing laboratory division that provides consulting and laboratory services to medical companies that design and manufacture biomedical devices and drugs, as well as testing of products and the Company’s products. The Company’s key technology, Microcyn is based on electrically charged oxychlorine small molecules designed to target a range of pathogens that cause disease. The Company completed Phase II trials for Microcyn technology.